ThirtyFiveBio were delighted to make our data debut at the American Association for Cancer Research (AACR) 2023 conference. CEO, James Westcott, presented our groundbreaking data at AACR 2023 in a scientific poster. Our team and network of academic institutions, research organizations, and industry partners have been developing and testing our innovative approach of antagonising GPR35...
